Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. - Wikidata - wikimedia - TriplyDB

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

http://www.wikidata.org/entity/Q35691935

about

Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.Pancreatic cancer genomics: insights and opportunities for clinical translation Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.Erlotinib resistance in lung cancer: current progress and future perspectives.Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma Pancreatic stellate cell: Pandora's box for pancreatic disease biology.ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Prospects for MEK inhibitors for treating cancer.Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer.Cellular and molecular aspects of pancreatic cancer.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

P2860

Q30300846-75942ACB-3B3C-4364-B8EB-F8314BDBF186 Q30410012-AB207D39-C58E-4D63-BF70-804F77A38685 Q30422319-6F83860A-8895-4E69-9E4A-397E3B185CDA Q33566753-EF57EF58-8EB9-4396-B8C8-BA98D2D9A1BB Q33781071-F673940B-8B57-4E75-A220-314E2152536D Q34128812-CE0E8B8E-0155-49B8-954F-C4DB35232531 Q34187277-2235226A-FA67-481D-80BC-7F6AE87D57ED Q34465240-6E951935-1F57-4F8F-9F6F-FDB58A2E977C Q34680322-A8518B79-D31E-4FDD-AA9F-7E6D6E1BBA3A Q35152542-B6A68686-FB11-419F-983B-92352C6BDB9A Q35578544-C3A61A14-10EA-450B-8B12-0B9D0664F172 Q35657842-E34538A5-A9BF-4362-8246-D99620A6536F Q35691904-1B529B5B-0EB9-4114-8BDE-F82DDEF9408A Q35987390-4D76FE17-2F06-4055-BEFB-9FD546F81E02 Q36108221-0A832C8A-7A1F-424D-8CDF-10EF72228CBD Q36410371-E9EDE1B0-EFFF-4848-8C6C-528B3C7F7382 Q36437111-2E4E9448-6FEF-4FD5-9325-B9A56B14F834 Q36605522-45FD072D-8B3E-49A8-8FA1-C02132632FDB Q37238675-0A961B89-A1B1-45BF-A865-717482AE4CA4 Q37268998-9FAA279B-FBAA-4F3B-8032-ACBABD568D68 Q37411831-11800B7C-0846-453B-BFB5-37181924A3DC Q37593264-A22CA24D-E5B7-47B0-A84F-0C114931924D Q37609193-74781D59-B9C0-4B43-A137-715030E194FF Q37624480-EBBCB6A1-6270-4135-9812-6FACDD94789E Q37661108-5BAB17E5-FE6B-4155-A34A-5CBFEC90A135 Q38053855-D98E4E0E-215A-40D9-927E-69C5C2EFDBE0 Q38193520-7CA15168-06DC-4F85-B68E-BC62BE1DACCD Q38608075-E123155C-859D-4190-8DA8-88F3B2273831 Q38730160-8440EC64-C997-464B-9611-737DEDB9B02E Q38760434-526867E6-D550-41C4-9290-431A9DF02923 Q38761458-9130019B-336E-43C6-93A1-2F8813E0BC1A Q38902585-96D2973D-0DF2-48B6-B8D2-BB0A3F447B6C Q38908575-092BACE8-45D1-4FBA-A6CD-D555824F36DD Q39268126-7F20E04E-281D-4508-AE6E-77FC70945C5C Q41064400-EFB3762D-8427-4E5F-B2D9-13AB7BEBFE53 Q42678871-AD6C2084-0E97-43C0-90E9-A015BFD02548 Q47141971-2903961C-FB87-4FA2-926B-5D96D00F5273

P2860

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

http://www.wikidata.org/entity/Q35691935

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Synergistic effect between erl ...... human pancreatic cancer cells.

@ast

Synergistic effect between erl ...... human pancreatic cancer cells.

@en

type

label

Synergistic effect between erl ...... human pancreatic cancer cells.

@ast

Synergistic effect between erl ...... human pancreatic cancer cells.

@en

prefLabel

Synergistic effect between erl ...... human pancreatic cancer cells.

@ast

Synergistic effect between erl ...... human pancreatic cancer cells.

@en

P1433

Q35691935-EF33A353-06BE-4F8B-A838-DCCBB7C56D61

P1476

Q35691935-1E35B101-6FDD-421F-ABE8-BB6BD2F5D95D

P2093

Q35691935-6D61087C-EAA1-4206-9F13-A8481353E78E

Q35691935-8CDA5562-7CC8-4EFC-AB2F-ABC68A634C63

Q35691935-B87D8CBB-F7E5-4420-BA1C-829314FDA446

Q35691935-DBAAC242-9BC1-4D8C-8437-200F698BF49F

Q35691935-FFE3CEB1-6455-41B8-B2AA-6C116D6B63D4

P2860

Q35691935-0D1A4F04-6394-4128-9A0B-025121C061DC

Q35691935-1222DA49-9A03-4DAA-9D40-516A9590229E

Q35691935-1B049995-5E46-4B44-B9E7-CCBDF9B5A127

Q35691935-1D4B676F-BF9C-4E46-BBD6-51EB3BE2D2E4

Q35691935-1DF7A258-85EB-4F68-9C94-9919D9339222

Q35691935-20118DD6-6F86-4FB3-A6AA-E641434FCE1B

Q35691935-208EA9BE-C045-4CA0-9820-44F14E6035C3

Q35691935-247BB5B8-E27A-492C-8D0A-2E6C7689287B

Q35691935-29D747BB-6F8C-490E-8A94-D800318CD2F6

Q35691935-2E56B8E1-CEFF-4688-9180-4BEA77B36539

P304

Q35691935-8A28EE5A-E6AF-443F-9469-4C0466A3DCC3

P31

Q35691935-EE8E4820-0022-4EDD-BCC4-191C5FAAD64B

P356

Q35691935-C4833AD5-6789-4B21-94CD-588E4DF95E0E

P407

Q35691935-734A50E8-3635-492E-8BEE-D853A0F94C36

P433

Q35691935-CA9408C9-ADBB-4C95-A342-7D012BA73B4C

P478

Q35691935-0004C4FD-941F-430A-9BBC-A505281F9FD0

P577

Q35691935-6C7BCE7A-AC8B-4C92-9FCA-424D3E4633E1

P5875

Q35691935-DCCF2201-9D08-4FFB-86C3-B255976F9C5C

P698

Q35691935-B95F51B0-45B3-4817-9EF5-AABD8C76B299

P932

Q35691935-2D9C5EE1-6F3B-4411-A95F-0FD7E8ADADC3

P356

1078-0432.CCR-10-2214

P1433

Clinical Cancer Research

P1476

Synergistic effect between erl ...... human pancreatic cancer cells.

@en

P2093

Ashish Choudhary

http://www.w3.org/2001/XMLSchema#string

Caroline H Diep

http://www.w3.org/2001/XMLSchema#string

Daniel D Von Hoff

http://www.w3.org/2001/XMLSchema#string

Haiyong Han

http://www.w3.org/2001/XMLSchema#string

Ruben M Munoz

http://www.w3.org/2001/XMLSchema#string

P2860

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Molecular physiology of mammalian glucokinase

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

P304

2744-2756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2214

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50348056

http://www.w3.org/2001/XMLSchema#string

P698

21385921

http://www.w3.org/2001/XMLSchema#string

P932

3265169

http://www.w3.org/2001/XMLSchema#string